Chinese Officials Helped Cover Up Lead Poisoning of Children, Report Says
The authorities in Gansu Province also accused education officials in the city of Tianshui of turning a blind eye to the fact that the kindergarten in question was unlicensed and accepted unauthorized gifts from an investor in the school. Food safety inspections at the school were perfunctory, according to an official report released on Sunday by a special investigative team convened by the Gansu provincial Communist Party committee and government.
Even before the release of the report, the lead poisoning scandal had dominated public discussion for weeks in China, where food safety has been a long-running concern.
The poisoning stemmed from powdered pigments that the school staff had used as food coloring, the report said. Some of the pigments, which were marked as inedible on its packaging, consisted of more than 20 percent lead; lead levels in the food the children were given exceeded the national food safety standard by 2,000 times.
But the investigation results further fueled public outrage at the official misconduct on multiple levels. Some parents at the preschool had already said they suspected a cover-up, even taking their children to other provinces for testing. Now their fears were confirmed.
One child was found to have elevated levels of lead six times over the course of half a year, starting in November 2024, without the hospital, Tianshui No. 2 People's Hospital, issuing any alert, the report said. The hospital also modified the records of two more children who showed elevated lead levels, reporting a blood lead level nearly seven times lower than the actual result for one of them.
Want all of The Times? Subscribe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
16 minutes ago
- Medscape
EMA Recommends Eco-Friendly Inhaler for COPD
The European Medicines Agency (EMA) has recommended a change in composition for Trixeo Aerosphere, also known as Riltrava Aerosphere. Both drugs are used for maintenance treatment in a subset of adults with moderate-to-severe chronic obstructive pulmonary disease (COPD). The recomposition involves replacing the existing gas propellant, HFA-134a, with a low global warming-potential (GWP) gas alternative called HFO-1234ze(E). The propellant is used for drug delivery and is not an active medicine. AstraZeneca claims that the new propellant will lead to a 99.9% reduction in GWP and an 85% reduction in greenhouse gas emissions compared with current propellants. The company adds that its carbon footprint is similar to that of dry powder inhalers. The reformulation was approved by British regulators in May and is currently under review in other countries such as China. COPD is an umbrella term for a group of lung conditions, including emphysema and chronic bronchitis. Symptoms include shortness of breath, frequent chest infections, and persistent wheezing. Estimates suggest that around 36.5 million people had COPD in Europe in 2020, and that this number will increase to 49.5 million by 2050. Trixeo Aerosphere and Riltrava Aerosphere have three active ingredients: budesonide, glycopyrronium, and formoterol fumarate dihydrate. Budesonide is a glucocorticosteroid that exerts rapid, dose-dependent, anti-inflammatory action on the airways when inhaled. Meanwhile, glycopyrronium is a long-acting muscarinic antagonist and formoterol fumarate dihydrate is a selective beta2-adrenergic agonist. Both result in bronchodilation. The reformulation comes as the EU phases out high GWP gases for environmental reasons. The EMA reported that studies confirm the safety and efficacy of the reformulated medicine are equivalent to those of the currently approved product. The associated studies will be made available in the variation assessment report following the European Commission's final decision, which is expected in the coming weeks. Annie Lennon is a medical journalist. Her writing appears on Medscape, WebMD, and Medical News Today, among other outlets.
WIRED
a day ago
- WIRED
An Inventor Is Injecting Bleach Into Cancerous Tumors—and Wants to Bring the Treatment to the US
Xuewu Liu, a Chinese inventor who has no medical training or credentials of any kind, is charging cancer patients $20,000 for access to an AI-driven but entirely unproven treatment that includes injecting a highly concentrated dose of chlorine dioxide, a toxic bleach solution, directly into cancerous tumors. One patient tells WIRED her tumor has grown faster since the procedure and that she suspects it may have caused her cancer to spread—a claim Liu disputes—while experts allege his marketing of the treatment has likely put him on the wrong side of US regulations. Nonetheless, while Liu currently only offers the treatment informally in China and at a German clinic, he is now working with a Texas-based former pharmaceutical executive to bring his treatment to America. They believe that the appointment of Robert F. Kennedy Jr. as health secretary will help 'open doors' to get the untested treatment—in which at least one clinic in California appears to have interest—approved in the US. Kennedy's Make America Healthy Again (MAHA) movement is embracing alternative medicines and the idea of giving patients the freedom to try unproven treatments. While the health secretary did not respond to a request for comment about Liu's treatment, he did mention chlorine dioxide when questioned about President Donald Trump's Operation Warp Speed during his Senate confirmation hearing in February, and the Food and Drug Administration recently removed a warning about substance from its website. The agency says the removal was part of a routine process of archiving old pages on its site, but it has had the effect of emboldening the bleacher community. 'Without the FDA's heavy-handed warnings, it's likely my therapy would have been accepted for trials years earlier, with institutional partnerships and investor support,' Liu tells WIRED. He says he wrote to Kennedy earlier this year urging him to conduct more research on chlorine dioxide. 'This quiet removal won't immediately change everything, but it opens a door. If mainstream media reports on this shift, I believe it will unlock a new wave of serious [chlorine dioxide] research.' For decades, pseudoscience grifters have peddled chlorine dioxide solutions—sold under a variety of names, such as Miracle Mineral Solution—and despite warnings and prosecutions, have continued to claim the toxic substance is a 'cure' for everything from HIV to Covid-19 to autism. There is no credible evidence to back up any of these claims, which critics have long labeled as nothing more than a grift. The treatments typically involve drinking liquid chlorine dioxide on a regular basis, using solutions with concentrations of chlorine dioxide of around 3,000 parts per million (ppm), which is diluted further in water. Liu's treatment, however, involves a much higher concentration of chlorine dioxide—injections of several milliliters of 20,000ppm—and, rather than drinking it, patients have it injected directly into their tumors. Liu claims he has injected himself with the solution over 50 times and suffered no side effects. 'This personal data point encouraged me to continue research,' he says.
Medscape
a day ago
- Medscape
What Factors Influence a Patient's Success on GLP-1s?
Longer treatment duration, not having diabetes, and using semaglutide were among the factors associated with better weight reduction over 12 months among patients taking GLP-1 receptor agonists (RA), a cohort study suggested. 'Treatment responses differ among patients receiving GLP-1 RAs, and the weight fluctuations and associated factors following [their] use have not been adequately characterized,' Linong Ji, MD, of Peking University People's Hospital in Beijing, China, told Medscape Medical News . The findings, published online in Diabetes, Obesity and Metabolism , 'may provide novel insights into weight fluctuations after GLP-1 RA treatment in a real-world setting,' he said, potentially advancing the development of individualized strategies for patients. 'Corroborates Other Studies' Researchers conducted a real-world, single-center, retrospective study of 679 patients with overweight or obesity who initiated GLP-1 RA treatment between November 2022 and October 2024. At baseline, participants had a mean age of 37 years, and 31% were men. The mean BMI was 33.4, and 21% were diagnosed with diabetes. The GLP-1 RAs used in the study included semaglutide (Ozempic), liraglutide (Victoza), lixisenatide (Lyxumia), beinaglutide (Yishengtai), exenatide (Bydureon), dulaglutide (Trulicity), and PEG-loxenatide (Fulaimei). All were available for participants with both type 2 diabetes (T2D) and overweight/obesity. For participants with overweight/obesity but without T2D, only Ozempic or Victoza were routinely prescribed, with off-label documentation and informed consent. Weight measurements were collected during in-person clinic visits, and weight fluctuation curves were stratified into three phenotypes — Successful Weight Reduction, Remaining Stable, and Weight Regain. Subsequently, the association between potential influencing factors and weight fluctuations was estimated by univariate and multivariate logistic regression. Subgroup analyses were performed in participants with obesity, prediabetes, and in those using liraglutide or semaglutide. Researchers found significant differences in the duration of GLP-1 RA treatment across groups at the 3-, 6-, and 12-month follow-ups. The Successful Weight Reduction group had a significantly longer duration of GLP-1 RA treatment than the Remaining Stable group and a longer duration at both the 6- and 12-month follow-ups than the Weight Regain group. Diabetes status also showed group differences. At both the 3- and 6-month follow-ups, the proportion of patients with T2D in the Successful Weight Reduction group was lower than in the Remaining Stable group. Types of GLP-1 RAs varied between groups, and at the 3- and 6-month follow-ups, the Successful Weight Reduction group was more likely to have initiated treatment with semaglutide than the Remaining Stable group. Patients with a longer duration of GLP-1 RA treatment (odds ratio [OR], 1.014) and higher Homeostasis Model Assessment of Beta-Cell Function levels (OR, 4.912) were more likely to achieve successful weight reduction at the 12-month follow-up. Nondiabetic status (OR, 2.176) and using semaglutide (OR, 2.138) were associated with successful weight reduction at the 6-month follow-up. In addition, a higher percentage of body fat in both men (OR, 3.990) and women (OR, 2.266) was associated with successful weight reduction. The weight regain group had a higher baseline estimated glomerular filtration rate than the Successful Weight Reduction group and the Remaining Stable group at 3-month follow-up, especially among participants with prediabetes. Ji said this finding surprised him. Patients with obesity often exhibit a state of renal hyperfiltration, characterized by elevated renal plasma flow and glomerular filtration rate, which can be reversed by weight reduction. The finding suggests that patients with renal hyperfiltration might be less likely to experience durable weight reduction, Ji said. 'However, few studies have revealed similar observations. Therefore, further validations and investigations are still needed for this finding.' Furthermore, the team found a positive nonlinear association of serum creatinine with successful weight reduction at 12 months — a finding that will also require additional investigations to examine the mechanism underlying the association. Overall, Ji concluded that while longer duration of GLP-1 RA treatment using semaglutide, nondiabetic status, and higher percentage of body fat might be associated with better weight reduction, 'basal metabolic rate, skeletal muscle mass, muscle mass of the abdomen and limbs, and serum creatinine were nonlinearly associated with the probability of successful weight reduction.' Randy Seeley, MD, Henry King Ransom Endowed Professor of Surgery, Internal Medicine, and Nutritional Sciences at the University of Michigan School of Medicine, Ann Arbor, Michigan, and director of the National Institutes of Health-funded Michigan Nutrition Obesity Research Center, told Medscape Medical News , 'The main results of the study agree with what the field has already seen. Although it is a relatively small study, it corroborates other larger studies,' said Seeley, who was not involved in the study. This work was supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project. Ji reported receiving fees for lecture presentations and for consulting from AstraZeneca, Merck, Metabasis, MSD, Novartis, Eli Lilly and Company, Roche, Sanofi-Aventis, and Takeda. Seeley reported that his lab has worked with both Novo and Lilly (and others trying to enter the space), and he has also served as a paid consultant for both of those companies (and others trying to enter the space).
